The global demand for Prostate Cancer Diagnostics Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022-2028.
Prostate cancer is among the most frequent cancer type in the male. This cancer appears in the prostate in a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. Health practitioners do tests to analyze and comprehend the seriousness and learn if malignant growth has spread to other body locations from where it started. Doctors may also do tests to know which treatments could work best. Most prostate cancers are first found due to screening with PSA tests, CTC tests, immunohistochemistry, digital rectal exam, imaging test, and PCA3 test.
Market Dynamics
The rising prevalence of prostate cancer worldwide is driving the global prostate cancer diagnostics market. Prostate cancer is the fifth dominating cause of death worldwide and the second most frequent cancer diagnosis made in men. According to GLOBOCAN estimates, in 2018, 1,276,106 new prostate cancer cases were reported globally, with a higher burden in the developed countries. Differences in the prevalence rates worldwide reflect differences in the use of diagnostic testing. However, lack of awareness, high cost of diagnosis, and inadequate healthcare facilities in rural areas hinder the market growth.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of prostate cancer diagnostics.
Market Segmentation
This section of the prostate cancer diagnostics market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Test Type
- PSA Tests
- CTC Tests
- Immunohistochemistry
- PCA3 Test
- Digital Rectal Exam
- Imaging Test
- Others
By End User
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
By Type
- Prostatic Adenocarcinoma
- Small Cell Carcinoma
- Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Prostate Cancer Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Prostate Cancer Diagnostics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the prostate cancer diagnostics market include Abbott Laboratories, Biocept, Inc., AstraZeneca plc., Cancer Genetics, Inc., Danaher Corporation, Bayer Aktiengesellschaft, Becton, Dickinson and Company, Agilent Technologies, Foundation Medicine, Inc.S. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.